Related references
Note: Only part of the references are listed.Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial
Thomas A. Wadden et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, doubleblind, double-dummy, placebo-controlled, phase 3 trial
Melanie Davies et al.
LANCET (2021)
Once-Weekly Semaglutide in Adults with Overweight or Obesity
John P. H. Wilding et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Fibroblast growth factor (FGF)-21 based therapies: A magic bullet for nonalcoholic fatty liver disease (NAFLD)?
Michael Ritchie et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
An evaluation of liraglutide including its efficacy and safety for the treatment of obesity
Chen-Hsiu Lin et al.
EXPERT OPINION ON PHARMACOTHERAPY (2020)
New drugs for NAFLD: lessons from basic models to the clinic
Katharina C. Reimer et al.
HEPATOLOGY INTERNATIONAL (2020)
Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme
Tina K. Thethi et al.
DIABETES OBESITY & METABOLISM (2020)
Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs
Awadhesh Kumar Singh et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2020)
Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
Robert F. Kushner et al.
OBESITY (2020)
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design
Donna H. Ryan et al.
AMERICAN HEART JOURNAL (2020)
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Francis S. Willard et al.
JCI INSIGHT (2020)
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review
Xiaodan Lv et al.
ENDOCRINOLOGY DIABETES & METABOLISM (2020)
Semaglutide lowers body weight in rodents via distributed neural pathways
Sanaz Gabery et al.
JCI INSIGHT (2020)
Sarcopenia: revised European consensus on definition and diagnosis
Alfonso J. Cruz-Jentoft et al.
AGE AND AGEING (2019)
GLP-1's role in neuroprotection: a systematic review
Damla Erbil et al.
BRAIN INJURY (2019)
SCO-792, an enteropeptidase inhibitor, improves disease status of diabetes and obesity in mice
Hiroaki Yashiro et al.
DIABETES OBESITY & METABOLISM (2019)
The Discovery and Development of Liraglutide and Semaglutide
Lotte Bjerre Knudsen et al.
FRONTIERS IN ENDOCRINOLOGY (2019)
Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials
V. R. Aroda et al.
DIABETES & METABOLISM (2019)
Psychosocial Concerns Following Bariatric Surgery: Current Status
Melissa A. Kalarchian et al.
CURRENT OBESITY REPORTS (2019)
Pharmacological Prevention of Cardiovascular Outcomes in Diabetes Mellitus: Established and Emerging Agents
David R. Saxon et al.
DRUGS (2018)
Gut hormone polyagonists for the treatment of type 2 diabetes
Sara J. Brandt et al.
PEPTIDES (2018)
Amylin - Its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity
Christina Neuner Boyle et al.
MOLECULAR METABOLISM (2018)
The MIC-1/GDF15-GFRAL Pathway in Energy Homeostasis: Implications for Obesity, Cachexia, and Other Associated Diseases
Vicky W. W. Tsai et al.
CELL METABOLISM (2018)
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
Patrick M. O'Neil et al.
LANCET (2018)
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Juan Pablo Frias et al.
LANCET (2018)
GDF15 tells the brain to lose weight
M. Teresa Villanueva
NATURE REVIEWS DRUG DISCOVERY (2017)
Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity
John Blundell et al.
DIABETES OBESITY & METABOLISM (2017)
Sarcopenic obesity, weight loss, and mortality: the English Longitudinal Study of Ageing
Mark Hamer et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2017)
Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis
Zin Z. Htike et al.
DIABETES OBESITY & METABOLISM (2017)
Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis
Laura J. Carbone et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2016)
Does salmon calcitonin cause cancer? A review and meta-analysis
G. Wells et al.
OSTEOPOROSIS INTERNATIONAL (2016)
KBP-088, a novel DACRA with prolonged receptor activation, is superior to davalintide in terms of efficacy on body weight
Sofie Gydesen et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2016)
Probability of an Obese Person Attaining Normal Body Weight: Cohort Study Using Electronic Health Records
Alison Fildes et al.
AMERICAN JOURNAL OF PUBLIC HEALTH (2015)
Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure
Jonatan Ising Bagger et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
Jesper Lau et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Serum Levels of Human MIC-1/GDF15 Vary in a Diurnal Pattern, Do Not Display a Profile Suggestive of a Satiety Factor and Are Related to BMI
Vicky Wang-Wei Tsai et al.
PLOS ONE (2015)
Amylin: Pharmacology, Physiology, and Clinical Potential
Debbie L. Hay et al.
PHARMACOLOGICAL REVIEWS (2015)
Treat-to-target trials: uses, interpretation and review of concepts
A. J. Garber
DIABETES OBESITY & METABOLISM (2014)
Expression of concern—Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial
The Lancet Editors
LANCET (2013)
Food and Drug Administration's Obesity Drug Guidance Document A Short History
Eric Colman
CIRCULATION (2012)
Glucagon-Like Peptide-1 and its Cardiovascular Effects
Kyung-Sun Heo et al.
CURRENT ATHEROSCLEROSIS REPORTS (2012)
Influence of weight discrimination on weight loss goals and self-selected weight loss interventions
S. Sharma et al.
CLINICAL OBESITY (2011)
The Role of Pramlintide for Weight Loss
Kaelen C. Dunican et al.
ANNALS OF PHARMACOTHERAPY (2010)
Increased Fibroblast Growth Factor 21 in Obesity and Nonalcoholic Fatty Liver Disease
Jody Dushay et al.
GASTROENTEROLOGY (2010)
The role of peptide YY in appetite regulation and obesity
Efthimia Karra et al.
JOURNAL OF PHYSIOLOGY-LONDON (2009)
Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial
Arne Astrup et al.
LANCET (2008)
PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans
Rachel L. Batterham et al.
NATURE (2007)
Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients
N Finer et al.
DIABETES OBESITY & METABOLISM (2006)
Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters
CW le Roux et al.
ANNALS OF SURGERY (2006)
Share Paper
